Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

Aim: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). Methods: A probabilistic Markov model (second-order Monte Carlo simulat...

Full description

Bibliographic Details
Main Authors:	Ricardo Ginestal, Carlos Rubio-Terres, Olga Duran Moran, Dario Rubio-Rodriguez, Heidi De Los Santos, Cristina Ordonez, Isabel Sanchez-Magro
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-01-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	cladribine tablets cost–effectiveness dimethyl fumarate multiple sclerosis relapsing-remitting multiple sclerosis

Similar Items

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
by: Mohamed AlJumah, et al.
Published: (2020-02-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01)

Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra
by: A. A. Sokolova, et al.
Published: (2024-06-01)

Patients monitoring during treatment with Dimethyl fumarate (ORP-23)
by: Ali Yousefi Pour
Published: (2023-01-01)

Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis
by: Jerome de Seze, et al.
Published: (2024-04-01)

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
by: Massimo Filippi, et al.
Published: (2024-04-01)

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice
by: S. V. Petrov, et al.
Published: (2020-08-01)

Treatment of Multiple Sclerosis with Cladribine Tablets: Literature Review and the Guidance of the Lithuanian Association of Neurologists
by: R. Kizlaitienė, et al.
Published: (2024-03-01)

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study
by: Jeske van Pamelen, et al.
Published: (2025-02-01)

Assessment of the impact of reconstitution therapies—cladribine tablets and alemtuzumab—on the atrophy progression among patients with relapse-remitting multiple sclerosis
by: Aleksandra Pogoda-Wesołowska, et al.
Published: (2025-02-01)

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis
by: K. Z. Bakhtiyarova, et al.
Published: (2020-06-01)

Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
by: N. A. Totolyan, et al.
Published: (2020-10-01)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
by: Karolina Kania, et al.
Published: (2022-05-01)

Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice
by: Bassem Yamout, et al.
Published: (2024-08-01)

Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
by: Federico Carlini, et al.
Published: (2023-07-01)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
by: Lilyana Amezcua, et al.
Published: (2023-04-01)

A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Angel Chinea, et al.
Published: (2020-05-01)

Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
by: Jonathan Ciron, et al.
Published: (2024-03-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Mitzi J. Williams, et al.
Published: (2020-05-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
by: Dipen Sangurdekar, et al.
Published: (2019-11-01)

Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study
by: Giovanna Borriello, et al.
Published: (2024-07-01)

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)

Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases
by: Azzam Maghazachi, et al.
Published: (2016-07-01)

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
by: Jihad Inshasi, et al.
Published: (2023-06-01)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
by: Neda Sattarnezhad, et al.
Published: (2022-07-01)

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
by: Heinz Wiendl, et al.
Published: (2025-02-01)

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
by: Heinz Wiendl, et al.
Published: (2025-03-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
by: Pierre Clavelou, et al.
Published: (2023-06-01)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
by: Vanesa Cunill, et al.
Published: (2018-05-01)

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
by: Mitzi J. Williams, et al.
Published: (2023-06-01)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
by: Maddalena Ruggieri, et al.
Published: (2020-08-01)

New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate
by: Paolinelli Matteo, et al.
Published: (2022-12-01)

CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
by: Damiano Marastoni, et al.
Published: (2024-02-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
by: David Haschka, et al.
Published: (2020-04-01)